Research · Updated 26 Oct, 12:59 am IST

Moderna and Merck say personalized mRNA cancer vaccine cut melanoma death, recurrence 42%

Why it matters for readers: If you follow health news, it shows a major advance in using mRNA technology to try to prevent cancer returning.

Moderna and Merck reported a personalized mRNA cancer vaccine lowered death and recurrence by 42% in melanoma patients.1
The result was presented as clinical trial data announced in October 2026.1
The vaccine is described as a personalized mRNA therapy targeting melanoma.1

Get a brief like this every morning

Uzha reads hundreds of sources and gives you the stories that matter for your work, with every source linked. Free.